3 coronavirus stocks I’d buy (and some I’d avoid)

The Covid-19 pandemic is changing society in many ways. Here are three coronavirus stocks I’d buy, and some I’d steer clear of.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The coronavirus pandemic has impacted stocks in wildly differing ways. Of course, with the FTSE All-Share index down over 20% since the start of the year, the impact has been severely negative for many stocks.

However, a perhaps surprising number are showing good gains for the year. This, in spite of – or, in some cases, because of – the Covid-19 pandemic. Here, I want to tell you about three coronavirus stocks I’d buy today, and some I’d avoid.

Big pharma

The world’s big pharma companies are working to develop vaccines for Covid-19. They’re hopeful of success. GlaxoSmithKline CEO Emma Walmsley said yesterday she’s optimistic the industry will be able to make an immunisation against Covid-19. And that it’ll be widely available next year.

In the meantime, we’re making progress on treatments that alleviate the impact of the coronavirus. And more will surely be developed. It seems likely we’ll be in a much better place in 2021 than we’ve been in this year.

Big pharma firms like GlaxoSmithKline could make money from vaccines. But for these multi-billion-pound giants it would be just one of many revenue streams. In other words, Covid-19 isn’t the be-all and end-all for them.

Coronavirus stocks I’d avoid

For small companies, a Covid-19 ‘breakthrough’ could have a big impact. I’ve lost track of the number of UK small-caps that have announced they’re working on some Covid-19-related product or service. Traders and speculators seem to have jumped on such announcements, pushing these companies’ shares up to often crazy valuations.

I’d be inclined to avoid any loss-making small-cap that’s garnered investor interest purely on the back of a tilt at a Covid-19 product or service. I suspect most such companies will fall back into obscurity and their share prices to pre-pandemic levels.

In short, I think investors are on dangerous ground backing profitless small-caps that have made speculative – or in some cases fairly spurious – moves to profit from Covid-19.

Coronavirus stocks I’d buy

I’m much more interested in businesses that should benefit from changes in society that the coronavirus is producing or accelerating. I’m referring to things like online shopping and working from home.

Supermarket giant Tesco boldly doubled its online capacity in the first weeks of the pandemic. This took its market share of UK online grocery sales to 33.5%. Before the pandemic, I’d been impressed by the company’s turnaround and fight-back against discounters like Aldi and Lidl. These bricks-and-mortar discounters now have a lot of ground to make up online, as they acknowledge customer habits are changing. I rate Tesco a ‘buy’.

I’d also happily buy shares of Gamma Communications. It’s a leading supplier of unified communications services to the SME, public sector, and enterprise markets. It enables instant messaging, video calling, multi-party conferencing, and all sorts of other stuff. It’s set to benefit from a likely far larger number of people working from home, or partly from home, than before the pandemic.

Finally, I was keen on gold miners last year, due to the rising level of global debt. Due to the pandemic, money printing and debt have absolutely exploded. In my view, the debasing of paper currencies means we’ll see increasing demand for gold. As such, I think FTSE 100 gold miner Polymetal International is a good stock to buy to benefit from the financial fallout of Covid-19.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Is it time to consider gobbling up these 3 FTSE 100 Christmas turkeys?

Our writer looks at the pros and cons of buying three of the FTSE 100’s (INDEXFTSE:UKX) worst performers over the…

Read more »

Investing Articles

Are Rolls-Royce shares a ticking time bomb after a 95% gain in 2025?

Rolls-Royce shares have been defying predictions of a fall for years now, while consistently smashing through analyst expectations.

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

I asked ChatGPT for a discounted cash flow analysis for Lloyds shares. This is what it said…

AI software can do complicated calculations in seconds. James Beard took advantage and asked ChatGPT for its opinion on the…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Back to glory: is Aston Martin poised for growth stock stardom in 2026?

Growth stock hopes for Aston Martin quickly evaporated soon after flotation in 2018. But forecasts show losses narrowing sharply.

Read more »

British coins and bank notes scattered on a surface
Investing Articles

UK dividend stocks could look even more tempting if the Bank of England cuts rates this week!

Harvey Jones says returns on cash are likely to fall in the coming months, making the income paid by FTSE…

Read more »

Investing Articles

Up 115% with a 5.5% yield – are Aviva shares the ultimate FTSE 100 dividend growth machine?

Aviva shares have done brilliantly lately, and the dividend's been tip-top too. Harvey Jones asks if it's one of the…

Read more »

Investing Articles

How much do you need in a SIPP or ISA to target a second income of £36,000 a year in retirement?

Harvey Jones says a portfolio of FTSE 100 shares is a brilliant way to build a sustainable second income, and…

Read more »

Workers at Whiting refinery, US
Investing Articles

I own BP shares. Should I be embarrassed?

With more of a focus on ethical and overseas investing, James Beard considers whether it’s time to remove BP shares…

Read more »